Johnson & Johnson has priced its new Spravato nasal spray for treatment ... in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment ...

Q4 2024 Earnings Call Transcript March 4, 2025 Neuronetics, Inc. misses on earnings expectations. Reported EPS is $-0.33 EPS, expectations were $-0.26. Operator: Good day, and thank you for standing ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

And in for Spravato, we have 63 of our clinics that are ... I think the Q1 guide is $28 million to $30 million. That's a pretty healthy ramp throughout the year that's kind of embedded there ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Operating expenses during the fourth quarter of 2024 were $25.8 million, an increase of $5.6 million, or 28%, compared to $20.2 million in the fourth quarter of 2023, mainly attributable to ...

Also, the company’s net income and EPS grew 28.3% and 31.1% from the prior year’s quarter ... JNJ announced the U.S. FDA approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Standing on the shoulders of Johnson & Johnson's Spravato. Upcoming milestones and clinical trials. Psychedelic industry sentiment; RFK Jr influence. Pursuing social anxiety disorder with MDMA.

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...